Dequalinium chloride: new topical treatment for bacterial vaginosis

Fluomizin (dequalinium chloride) is a new option for the treatment of bacterial vaginosis. The vaginal tablet should be inserted at night for 6 days.

Resistance to dequalinium chloride is unlikely owing to the drug's broad bactericidal and fungicidal activity. | SCIENCE PHOTO LIBRARY
Resistance to dequalinium chloride is unlikely owing to the drug's broad bactericidal and fungicidal activity. | SCIENCE PHOTO LIBRARY

The bactericidal action of dequalinium chloride starts within 30–60 minutes of insertion. An increase in bacterial cell permeability causes a loss of enzyme activity and eventually cell death. Relief of bacterial vaginosis symptoms generally occurs within 24—72 hours; however, patients should be advised to complete the full treatment course in order to avoid a relapse.

Further information
View Fluomizin drug record
Summary of Product Characteristics
Manufacturer: Kora Healthcare
MIMS Women's Health Clinic

Latex condoms are not affected by dequalinium chloride but additional forms of contraception should be considered when non-latex condoms, diaphragms and other barrier contraceptives are used. Use of douches, intravaginal soaps and spermicides should be avoided.

Clinical cure

A randomised, single-blind study compared the efficacy of dequalinium chloride vaginal tablets with that of clindamycin 2% vaginal cream in 321 women with bacterial vaginosis.

Clinical cure rates at 7 days after treatment were 81.5% in women treated with dequalinium and 78.4% in clindamycin-treated women.

The total failure rate (non-responders and recurrences combined) was similar in the two treatment groups. Symptomatic culture-positive vulvovaginal candidosis was less common in patients using dequalinium than in those treated with clindamycin cream (2.5% vs 7.7%; p=0.06). There were no significant differences between the numbers of women in each group showing symptoms of vulvovaginal candidosis or positive cultures for Candida spp.

The most commonly reported adverse reactions in patients treated with dequalinium were vaginal discharge and vulvovaginal pruritus.

Dequalinium is currently available in lozenge form for treatment of severe sore throats.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases